AGNOSTIC DIAGNOSTICS
A next-generation sequencing-based diagnostic test to identify any and every pathogen from a single sample
A next-generation sequencing-based diagnostic test to identify any and every pathogen from a single sample
During a disease outbreak, an agnostic diagnostic (one that detects any pathogen) would be a powerful tool to help the public health response from day one. Next-generation sequencing (NGS) technologies can identify any pathogen present in a sample — including new pathogens. DRIVe is supporting the analytical and clinical validation of NGS-based agnostic diagnostic assays to bring this much-needed capability closer to commercialization for future pandemic preparation.
Companies we have partnered with on this program to date
DRIVe is starting with an NGS-based diagnostic that will cover all known and unknown respiratory RNA viruses. Partners will optimize their in-house NGS capabilities for commercial clinical use by:
A test that gives results within 24 hrs with sensitivity similar to molecular diagnostic assays
Assays designed for short and long-read sequencers
Clear regulatory strategies toward commercialization
Funding
Closed
11/30/21
BARDA's Division of Research, Innovation, and Ventures (DRIVe) is collaborating with multiple industry and academic partners to advance the ability to quickly respond to public health emergencies with a new...
AGNOSTIC DIAGNOSTICS program is closed
